Tag: Hypertension

Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension

SAN JOSE, Calif. and PARIS, Sept. 3, 2019 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market Clinical Trial, which were presented today during a symposium at the 2019 European Society […]

Ablative Solutions Announces Results from Treatment of Patients with Hypertension in the European Peregrine Post-Market Study

KALAMAZOO, Mich. & WASHINGTON–(BUSINESS WIRE)–Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced new data from the Peregrine Post-Market Clinical Trial, which were presented this week during a late-breaking session at the 2019 Cardiovascular […]

ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise® Ultrasound Denervation System For Treatment Of Hypertension

PALO ALTO, Calif., July 2, 2018 /PRNewswire/ — ReCor Medical announced today that the US Food & Drug Administration approved the Company’s new pivotal study of the Paradise Ultrasound Denervation System for the treatment of hypertension: RADIANCE-II. Building upon the recent positive […]

Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months

MOUNTAIN VIEW, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) — Vascular Dynamics, a privately held medical device company developing novel solutions for the treatment of hypertension, will present updated interim results of the company’s first-in-human trial of its MobiusHD® implant today at the […]

ReCor Medical Announces 1000th Enrollment and 150th Randomization in RADIANCE-HTN Hypertension Study

PALO ALTO, Calif., Oct. 30, 2017 /PRNewswire-USNewswire/ — ReCor Medical announced progress milestones in the study of its Paradise® Renal Denervation System as a potential treatment for hypertension, including the 1000th consented and the 150th randomized subjects in the RADIANCE-HTN study, and […]